---
title: "Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Natural history, survival, and mortality"
description: "Formulary evidence on Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Natural history, survival, and mortality. Topics: Fibrosis stage as the primary predictor of outcomes, with higher risk from F2 (at-risk NASH); All-cause and liver-related mortality by fibrosis stage: meta-analysis of 14 articles, 17,301 participants with biopsy-proven NAFLD; Mortality rate ratios by fibrosis stage: meta-analysis of 5 cohorts, 1,495 participants with NAFLD; Relative risk of mortality and liver events, stage 4 versus stage 0: meta-analysis of 13 studies, 4,428 participants with NAFLD; 13 further topics. 17 evidence topics quoted from 17 sources."
canonical: "https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/product-information-and-disease-description/natural-history-survival-and-mortality"
published: "2026-11-18T22:34:49-05:00"
modified: "2026-11-18T22:34:49-05:00"
---

# Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Natural history, survival, and mortality

<a id="heading-2.2.1.3"></a>

## 2.2.1.3 Natural History, Survival, and Mortality

<a id="topic-2.2.1.3-1"></a>

### Fibrosis stage as the primary predictor of outcomes, with higher risk from F2 (at-risk NASH)

> “Data from meta-analyses and pooled studies demonstrate that fibrosis and the presence of steatohepatitis are the primary predictors of disease progression.”
> “Nevertheless, patients with NASH and at least stage 2 fibrosis (F2), referred to as “at-risk” NASH, have a demonstrably higher risk of liver-related morbidity and mortality.”
> “The most common causes of death in patients with NAFLD overall are cardiovascular disease (CVD) and nonhepatic malignancy, followed by liver disease.”
> “Bridging fibrosis and cirrhosis are associated with an exponentially greater risk of liver-related morbidity and mortality than earlier stages of fibrosis.”
> “Among patients with cirrhosis, progression to clinical decompensation ranges from 3% to 20% per year.”

Source: [Rinella et al. (2023a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10735173/)

<a id="topic-2.2.1.3-2"></a>

### All-cause and liver-related mortality by fibrosis stage: meta-analysis of 14 articles, 17,301 participants with biopsy-proven NAFLD

> “Medline and Embase databases were searched to include cohort studies reporting survival outcomes by fibrosis stage in biopsy-proven NAFLD.”
> “A total of 14 articles involving 17,301 patients with NAFLD were included. All-cause mortality at 1, 5, and 10 years for stage 0 to 2 fibrosis was 0.1%, 3.3%, and 7.7% vs 0.3%, 20.6%, and 41.5% for stage 4 fibrosis.”
> “Compared with stage 0 fibrosis, all-cause mortality increased with fibrosis stage: stage 2; HR, 1.46 (95% confidence interval [CI], 1.08–1.98), stage 3; HR, 1.96 (95% CI, 1.41–2.72), and stage 4; HR, 3.66 (95% CI, 2.65–5.05).”
> “Risk for liver-related mortality increased exponentially as fibrosis stage increased: stage 2; HR, 4.07 (95% CI, 1.44–11.5), stage 3; HR, 7.59 (95% CI, 2.80–20.5), and stage 4; HR, 15.1 (95% CI, 5.27–43.4).”

Source: [Ng et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10792524/)

<a id="topic-2.2.1.3-3"></a>

### Mortality rate ratios by fibrosis stage: meta-analysis of 5 cohorts, 1,495 participants with NAFLD

> “1,495 NAFLD patients with 17,452 patient years of follow-up were included.”
> “Compared to NAFLD patients with no fibrosis (stage 0), NAFLD patients with fibrosis were at an increased risk for all-cause mortality and this risk increased with increase in the stage of fibrosis: stage 1, MRR, 1.58 (95% CI 1.19–2.11); stage 2, MRR, 2.52 (95% CI 1.85–3.42); stage 3, MRR, 3.48 (95% CI 2.51–4.83), and stage 4, MRR, 6.40 (95% CI 4.11–9.95).”
> “The results were more pronounced as the risk of liver-related mortality increased exponentially with increase in the stage of fibrosis: stage 1, MRR, 1.41 (95% CI 0.17–11.95); stage 2, MRR, 9.57 (95% CI 1.67–54.93); stage 3, MRR, 16.69 (95% CI 2.92–95.36); and stage 4, MRR, 42.30 (95% CI 3.51–510.34).”

Source: [Dulai et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5397356/)

<a id="topic-2.2.1.3-4"></a>

### Relative risk of mortality and liver events, stage 4 versus stage 0: meta-analysis of 13 studies, 4,428 participants with NAFLD

> “Our meta-analysis included 13 studies, comprising 4428 patients with NAFLD; 2875 of these were reported to have NASH.”
> “Compared with no fibrosis (stage 0), unadjusted risk increased with increasing stage of fibrosis (stage 0 vs 4): all-cause mortality RR, 3.42 (95% CI, 2.63-4.46); liver-related mortality RR, 11.13 (95% CI, 4.15-29.84); liver transplant RR, 5.42 (95% CI, 1.05-27.89); and liver-related events RR, 12.78 (95% CI, 6.85-23.85).”

Source: [Taylor et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32027911/)

<a id="topic-2.2.1.3-5"></a>

### Death or liver transplantation and liver-related events by fibrosis stage: 619 participants with biopsy-diagnosed NAFLD, median 12.6 years

> “We performed a retrospective analysis of 619 patients diagnosed with NAFLD from 1975 through 2005 at medical centers in the United States, Europe, and Thailand.”
> “Over a median follow-up of 12.6 years (range 0.3–35.1), 193 of the patients (33.2%) died or underwent liver transplantation. Features of liver biopsies significantly associated with death or liver transplantation included fibrosis stage 1 (HR, 1.88; 95% CI, 1.28, 2.77), stage 2 (HR, 2.89; 95% CI, 1.93, 4.33), stage 3 (HR, 3.76; 95% CI, 2.40, 5.89), and stage 4 (HR, 10.9; 95% CI, 6.06, 19.62) compared with stage 0”
> “Twenty-six patients (4.2%) developed liver-related events; fibrosis stage 3 (HR 14.2 [95% CI 3.38, 59.68]) and stage 4 (HR 51.5 [95% CI 9.87, 269.2]) compared to stage 0, were significantly associated with the events.”

Source: [Angulo et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4516664/)

<a id="topic-2.2.1.3-6"></a>

### Deaths and liver-related complications per 100 person-years by fibrosis stage: prospective NASH CRN cohort, 1,773 adults, median 4 years

> “A total of 1773 adults with NAFLD were followed for a median of 4 years. All-cause mortality increased with increasing fibrosis stages (0.32 deaths per 100 person-years for stage F0 to F2 [no, mild, or moderate fibrosis], 0.89 deaths per 100 persons-years for stage F3 [bridging fibrosis], and 1.76 deaths per 100 person-years for stage F4 [cirrhosis]).”
> “The incidence of liver-related complications per 100 person-years increased with fibrosis stage (F0 to F2 vs. F3 vs. F4) as follows: variceal hemorrhage (0.00 vs. 0.06 vs. 0.70), ascites (0.04 vs. 0.52 vs. 1.20), encephalopathy (0.02 vs. 0.75 vs. 2.39), and hepatocellular cancer (0.04 vs. 0.34 vs. 0.14).”
> “After adjustment for age, sex, race, diabetes status, and baseline histologic severity, the incidence of any hepatic decompensation event (variceal hemorrhage, ascites, or encephalopathy) was associated with increased all-cause mortality (adjusted hazard ratio, 6.8; 95% confidence interval, 2.2 to 21.3).”

Source: [Sanyal et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8881985/)

<a id="topic-2.2.1.3-7"></a>

### Mortality by histologic stage versus matched controls: Swedish nationwide biopsy cohort, 10,568 participants, median 14.2 years

> “This nationwide, matched cohort study included all individuals in Sweden with biopsy-confirmed NAFLD (1966–2017; n=10,568).”
> “Over a median of 14.2 years, 4,338 NAFLD patients died.”
> “Compared to controls, significant excess mortality risk was observed with simple steatosis (8.3/1000PY, aHR=1.71, 95%CI=1.64–1.79), non-fibrotic NASH (13.4/1000PY, aHR=2.14, 95%CI=1.93–2.38), non-cirrhotic fibrosis (18.4/1000PY, aHR=2.44, 95%CI=2.22–2.69) and cirrhosis (53.6/1000PY, aHR=3.79, 95%CI=3.34–4.30)”
> “The excess mortality associated with NAFLD was primarily from extra-hepatic cancer (4.5/1000PY; aHR=2.16, 95%CI=2.03–2.30), followed by cirrhosis (2.7/1000PY; aHR=18.15, 95%CI=14.78–22.30), cardiovascular disease (1.4/1000PY; aHR=1.35, 95%CI=1.26–1.44) and hepatocellular carcinoma (HCC)(1.2/1000PY; aHR=11.12, 95%CI=8.65–14.30).”

Source: [Simon et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8185553/)

<a id="topic-2.2.1.3-8"></a>

### Major adverse liver outcomes by fibrosis stage: Swedish cohort of 1,260 participants with non-cirrhotic NAFLD, median 13 years

> “Patients (n = 1,260) with NAFLD without cirrhosis were diagnosed through biopsy or radiology, and had fibrosis estimated through vibration-controlled transient elastography, biopsy, or FIB-4 score between 1974 and 2020 and followed up through 2020.”
> “MALO occurred in 111 (8.8%, incidence rate = 5.9/1,000 person-years) patients with NAFLD and 197 (1.6%, incidence rate = 1.0/1,000 person-years) reference individuals during a median follow up of 13 years.”
> “The 20-year cumulative incidences of MALO were 2% for the reference population, 3% for patients with F0, and 35% for F3.”
> “The adjusted hazard ratio (aHR) for F2, as determined by biopsy, was 2.9 (95% CI 1.5–5.5), and for F3 the aHR was 8.9 (95% CI 4.6–17.4), both compared with the reference group with F0–1.”

Source: [Akbari et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10827505/)

<a id="topic-2.2.1.3-9"></a>

### Progression to cirrhosis and all-cause mortality in non-cirrhotic MASH F2 and F3: US TARGET-NASH cohort, 2,378 participants

> “Among the 2378 patients included in this analysis, 48% had MASH cirrhosis.”
> “Among the 1425 patients with non-cirrhotic MASH, there were 982 patients in the F0–F1 cohort, 281 patients in the F2 cohort, and 162 patients in the F3 cohort (Supplemental Fig. 2).”
> “Incidence rates of cirrhosis increased from 0.34/100PM in the F0–F1 cohort to 1.24/100PM in the F2 cohort and 6.62/100PM in the F3 cohort (Table 5). Unadjusted risk of progressing to cirrhosis was highest among those with F3 (HR, 95% CI; 18.66, 10.97–31.73) and 3.74 times higher with F2 (HR, 95% CI; 3.74, 2.00–6.98) versus F0–F1 (Fig. 3).”
> “All-cause mortality was associated with disease severity and incidence rates increased from 0.14/100PM in the F0–F1 cohort to 0.3/100PM in the F2 cohort, 0.42/100PM in the F3 cohort, 2.02/100PM in the compensated cirrhosis cohort and 4.62/100PM in the decompensated cirrhosis cohort (Table 5).”
> “This analysis was supported by Novo Nordisk Inc., Plainsboro, NJ.”

Source: [Luthra and Sheth (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11787050/)

<a id="topic-2.2.1.3-10"></a>

### Fibrosis progression and regression rates and times by stage: meta-analysis of 54 paired biopsy or imaging studies

> “Time to progress by 1 fibrosis stage was 9.9, 10.3, 13.3 and 22.2 years for F0, F1, F2, and F3, respectively. Time to regress by 1 stage was 21.3, 12.5, 20.4, and 40.0 years for F4, F3, F2, and F1, respectively. Rates estimated from RCTs were higher than those from observational studies.”
> “In patients with F2, a similar proportion progressed, regressed, or remained stable (32%, 37%, and 31%, respectively) after 5 years. Patients with F3 regressed more often than progressed, 32% vs. 22%”
> “Pooled incidence of progression from F0, F1, F2, and F3 were 6.5, 6.9, 5.8, and 4.5/100 person-years, respectively (Table 3). Pooled incidence for regression from F1, F2, F3, and F4 were 2.5, 4.6, 6.0, and 4.7/100 person-years, respectively.”

Source: [Le et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9898457/)

<a id="topic-2.2.1.3-11"></a>

### Fibrosis progression rate in NASH versus NAFL: meta-analysis of 11 paired biopsy cohorts, 411 participants

> “We identified 11 cohort studies including 411 patients with biopsy-proven NAFLD (150 with NAFL and 261 with NASH).”
> “Over 2145.5 person-years of follow up, 33.6% had fibrosis progression, 43.1% had stable fibrosis, and 22.3% had improvement in fibrosis stage.”
> “These findings correspond to 1 stage of progression over14.3 years for patients with NAFL (95% CI, 9.1–50.0 years) and 7.1 years for patients with NASH (95% CI, 4.8–14.3 years).”

Source: [Singh et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4208976/)

<a id="topic-2.2.1.3-12"></a>

### Fibrosis progression in NASH and mortality rates in NAFLD and NASH: global meta-analysis

> “Fibrosis progression proportion, and mean annual rate of progression in NASH were 40.76% (95% CI: 34.69-47.13) and 0.09 (95% CI: 0.06-0.12).”
> “Liver-specific mortality and overall mortality among NAFLD and NASH were 0.77 per 1,000 (range, 0.33-1.77) and 11.77 per 1,000 person-years (range, 7.10-19.53) and 15.44 per 1,000 (range, 11.72-20.34) and 25.56 per 1,000 person-years (range, 6.29-103.80).”

Source: [Younossi et al. (2016a)](https://pubmed.ncbi.nlm.nih.gov/26707365/)

<a id="topic-2.2.1.3-13"></a>

### All-cause and cause-specific mortality among adults with NAFLD: global meta-analysis

> “Among the NAFLD population, the pooled mortality rate (n=3) in studies that had used ultrasound or serum diagnostic method was 12.60 per 1000 PY (6.68–23.67) for all-cause mortality; 4.20 per 1000 PY (1.34–7.05) for cardiac-specific mortality; 2.83 per 1000 PY (0.78–4.88) for extrahepatic cancer-specific mortality; and 0.92 per 1000 PY (0.00–2.21) for liver-specific mortality (Table 4).”

Source: [Younossi et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10026948/)

<a id="topic-2.2.1.3-14"></a>

### Progression from steatosis to steatohepatitis, effect of type 2 diabetes, and cause-specific mortality by histologic stage

> “It has been estimated that approximately 10–30% of persons with isolated steatosis progress to steatohepatitis and advanced liver disease, but the risk is much higher in the presence of T2D (42-65% have steatosis).”
> “In a Swedish population-based cohort of 10,568 adults with biopsy-confirmed MASLD and 49,925 matched general population comparators, mortality rates from cirrhosis and HCC were modestly elevated in simple steatosis (absolute rate differences, 1.2 and 0.7/1,000 person-years [PY], respectively), but these rates increased progressively in MASH without fibrosis (3.0 and 1.3/1,000 PY, respectively), non-cirrhotic fibrosis (5.5 and 2.5/1,000 PY, respectively) and cirrhosis (22.3 and 5.5/1,000 PY, respectively).”
> “in a study on 447 adult participants with MASLD and paired liver biopsies >1 year apart, individuals with T2D had a significantly higher cumulative incidence of fibrosis progression at 4 years (24% vs. 20%), 8 years (60% vs. 50%), and 12 years (93% vs. 76%) (p <0.005)”

Source: [European Association for the Study of the Liver (2024)](https://www.journal-of-hepatology.eu/article/S0168-8278%2824%2900329-5/fulltext)

<a id="topic-2.2.1.3-15"></a>

### US NAFLD-related decompensated cirrhosis, hepatocellular carcinoma, and liver deaths, projected 2015 to 2030, Markov model

> “Incident decompensated cirrhosis is forecasted to increase by 168%, from 39,320 cases annually in 2015 to 105,430 cases in 2030”
> “incident HCC cases are expected to increase by 137% from 5,160 to 12,240 in 2030 (Fig. 5).”
> “Liver deaths are projected at 78,300 in 2030, an increase of 178% from 2015 (Fig. 5).”

Source: [Estes et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5767767/)

<a id="topic-2.2.1.3-16"></a>

### US MASLD-related decompensated cirrhosis, liver cancer, and liver transplant, projected 2020 to 2050, microsimulation model

> “After 30 years, prevalent cases of decompensated cirrhosis would more than triple, while incident cases of liver cancer would almost double and liver transplant would almost quadruple.”

Source: [Le et al. (2025a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11742522/)

<a id="topic-2.2.1.3-17"></a>

### US deaths from chronic liver disease and cirrhosis of all causes, 2024

| Measure | Value |
| --- | --- |
| Number of deaths | “52,274” |
| Deaths per 100,000 population | “15.4” |
| Cause of death rank | “9” |

Source: [CDC FastStats chronic liver disease and cirrhosis (2026)](https://www.cdc.gov/nchs/fastats/liver-disease.htm)

## Related pages
- [Lanifibranor (IVA337): Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Terms and abbreviations](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/terms-and-abbreviations.md)
- [Lanifibranor (IVA337): Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/executive-summary.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Product information and disease description](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/product-information-and-disease-description.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Clinical evidence](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/clinical-evidence.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Economic information and modeling report](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/economics) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/economics.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: References](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/references) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/references.md)
